Abstract
The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.
| Original language | English |
|---|---|
| Article number | 26 |
| Journal | Journal of Translational Medicine |
| Volume | 2 |
| DOIs | |
| Publication status | Published - Jul 29 2004 |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Cancer immumotherapy : Avoiding the road to perdition. / Chiriva-Internati, Maurizio; Grizzi, Fabio; Bright, Robert K.; Kast, W. Martin.
In: Journal of Translational Medicine, Vol. 2, 26, 29.07.2004.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cancer immumotherapy
T2 - Avoiding the road to perdition
AU - Chiriva-Internati, Maurizio
AU - Grizzi, Fabio
AU - Bright, Robert K.
AU - Kast, W. Martin
PY - 2004/7/29
Y1 - 2004/7/29
N2 - The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.
AB - The hypothesis that human cancers express antigens that can be specifically targeted by cell mediated immunity has become a scientifically justifiable rationale for the design and clinical testing of novel tumor-associated antigens (TAA). Although a number of TAA have been recognized and it has been suggested that they could be useful in the immunological treatment of cancer, the complexity of human beings leads us to reflect on the need to establish new criteria for validating their real applicability. Herein, we show a system level-based approach that includes morphological and molecular techniques, which is specifically required to improve the capacity to produce desired results and to allow cancer immunotherapy to re-emerge from the mist in which it is currently shrouded.
UR - http://www.scopus.com/inward/record.url?scp=4344564149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4344564149&partnerID=8YFLogxK
U2 - 10.1186/1479-5876-2-26
DO - 10.1186/1479-5876-2-26
M3 - Article
VL - 2
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
SN - 1479-5876
M1 - 26
ER -